IP Library Granted Patent US 7,915,483
Granted Patent B2
US 7,915,483 · App. 11/874,607 · Granted Mar 29, 2011

C-terminally truncated interferon

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,915,483
App. No.
11/874,607
Granted
Mar 29, 2011
Kind
B2
Abstract

The invention described herein provides a C-terminally truncated interferon having a deletion of 7, 8, or 9 amino acids and having enhanced biological activity, and the polynucleotides encoding such an interferon. Also provided are methods for producing and using such truncated interferon. In some embodiments, the truncated interferon is produced in a plant.

Claims (11)

1. An artificial polynucleotide encoding a polypeptide comprising a C-terminally truncated interferon having enhanced anti-proliferative activity as compared to full length interferon, wherein said C-terminally truncated interferon consists of amino acids 1-156 of SEQ ID NO:2.

2. The artificial polynucleotide of claim 1 further comprising a nucleotide sequence that encodes the amino acid sequence of an extensin signal peptide.

3. The artificial polynucleotide of claim 1 , wherein said polynucleotide comprises a fragment of SEQ ID NO: 1 consisting of nucleotides 1-468.

4. A host plant cell comprising an expression vector wherein said vector comprises an artificial polynucleotide encoding a polypeptide comprising a C-terminally truncated interferon having enhanced anti-proliferative activity as compared to full length interferon, wherein said C-terminally truncated interferon consists of amino acids 1-156 of SEQ ID NO:2.

5. A process for producing a polypeptide comprising a C-terminally truncated interferon having enhanced anti-proliferative activity as compared to full length interferon; said process comprising transforming a plant with an expression vector wherein said vector comprises an artificial polynucleotide encoding a polypeptide comprising said C-terminally truncated interferon, wherein said C-terminally truncated interferon consists of amino acids 1-156 of SEQ ID NO:2.

6. The process of claim 5 comprising infecting the plant with a viral vector comprising the expression vector.

7. The process of claim 5 wherein the expression vector further comprises a nucleotide sequence that encodes the amino acid sequence of an extensin signal peptide.

8. The process of claim 5 comprising stably incorporating the expression vector into the genome of the plant.

9. A plant comprising an expression vector wherein said vector comprises an artificial polynucleotide encoding a polypeptide comprising a C-terminally truncated interferon having enhanced anti-proliferative activity as compared to full-length interferon, wherein said C-terminally truncated interferon consists of amino acids 1-156 of SEQ ID NO:2.

10. The plant of claim 9 wherein the expression vector is a viral vector.

11. The plant of claim 9 wherein the expression vector is stably incorporated into the plant genome.

Assignments (4)
RE-RECORD TO REMOVE 10874607 CORRECTIVE DOCUMENT AT R/F 025333/0026 Recorded Dec 30, 2010
From: BIOLEX THERAPEUTICS, INC.
To: MIDCAP FINANCIAL SBIC, LP
Reel/Frame 025714/0001 →
SECURITY AGREEMENT Recorded Nov 9, 2010
From: BIOLEX THERAPEUTICS, INC.
To: MIDCAP FINANCIAL SBIC, LP
Reel/Frame 025333/0026 →
CHANGE OF NAME Recorded Feb 12, 2008
From: BIOLEX, INC.
To: BIOLEX THERAPEUTICS, INC.
Reel/Frame 020487/0980 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 8, 2008
From: LARGE SCALE BIOLOGY CORPORATION
To: BIOLEX, INC.
Reel/Frame 020483/0484 →